NCT07108894View on ClinicalTrials.gov

A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

ABCL575

Participants will receive SC injection of ABCL575

BIOLOGICAL

Placebo (Normal Saline 0.9%)

Participants will receive SC injection of placebo (Normal Saline 0.9%)

Trial Locations (1)

H3P 3P1

RECRUITING

Altasciences Company Inc., Mount Royal

Sponsors
All Listed Sponsors
lead

AbCellera Biologics Inc.

INDUSTRY